← Leaderboards
Jessalyn Ubellacker
Harvard Medical School
$879,575
Attributed
$879,575
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $423.5K · FY2016–25$500K$375K$250K$125K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$879,575 · 2
By mechanism
R01$814,991 · 1
F31$64,584 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard Medical School
Same institution · by research overlap
- Arlene H Sharpe$68,359,602
- Christie Anne Ciarlo$99,232
- Georgia Stirtz$82,366
- Avram Lev Robinson-Mosher$163,110
- Jennifer A Lo$94,480
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsPrimary NeoplasmPreventMouse ModelCellsClinically RelevantMalignant Breast NeoplasmNeoplasm MetastasisTumor ProgressionAffectAdvanced DiseaseBoneBone MarrowBone Marrow CellsAcyl Coenzyme ACancer TypeBloodCancer CellBreast CarcinomaBisphosphonateCancer ModelCancer PrognosisCancer RecurrenceAdjuvant
Grant awards (4)
Preventing Melanoma Metastasis by Targeting Lipid Vulnerabilities in Lymph$391,523
R01 · FY2025 · CA · contact PI
Preventing Melanoma Metastasis by Targeting Lipid Vulnerabilities in Lymph$423,468
R01 · FY2024 · CA · contact PI
Elucidating the role of bisphosphonates in the inhibition of breast cancer$28,552
F31 · FY2017 · CA · contact PI
Elucidating the role of bisphosphonates in the inhibition of breast cancer$36,032
F31 · FY2016 · CA · contact PI